Загрузка...
A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors,
Olaparib (AZD2281) is an orally active Poly(ADP‐ribose) polymerase (PARP) inhibitor with favorable antitumor activity in advanced ovarian and breast cancers with BRCA1/2 mutations in Western (USA and European) studies. This Phase I dose‐finding study evaluated the tolerability, pharmacokinetics, PAR...
Сохранить в:
| Опубликовано в: : | Cancer Sci |
|---|---|
| Главные авторы: | , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Blackwell Publishing Ltd
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7713608/ https://ncbi.nlm.nih.gov/pubmed/22145984 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2011.02179.x |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|